LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Background Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tum...

Full description

Bibliographic Details
Main Authors: Ting Li, Wei Li, Ying Li, Sui Chen, Qian Gao, Xiaopeng Li, Po Zhang, Jinyang Hu, Feng Dong, You He, Xianyou Xia, Fangling Cheng, Xiaoshuang Hou, Guohao Liu, Minhai Dong, Qungen Xiao, Xingjiang Yu, Guifa Xi, Dongsheng Guo, Xudong Wu, Baofeng Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/9/e004452.full

Similar Items